

**Supplementary Table 5.** Daily dose of NOAC 6 months after the index date among patients with NVAF with at least 6 months' follow-up and still using a NOAC at 6 months.

	Lower dose than the index NOAC prescription		Same dose than the index NOAC prescription		Higher dose than the index NOAC prescription		Patients with at least 6 months' follow-up and who were still prescribed a NOAC at 6 months	Total patients with NVAF in the study
	n	%	n	%	n	%		
<b>Apixaban (N=6783)</b>	129	1.9	6362	95.4	201	3.0	<b>6667</b>	<b>10,834</b>
<b>Dabigatran (N=2874)</b>	72	2.5	2648	93.7	107	3.8	<b>2827</b>	<b>4381</b>
<b>Rivaroxaban (N=10,068)</b>	325	3.3	9265	95.0	160	1.6	<b>9750</b>	<b>15,252</b>
							<b>19,244</b>	<b>30,467</b>

NOAC, non-vitamin K antagonist oral anticoagulant, NVAF, non-valvular atrial fibrillation